Earnings summaries and quarterly performance for CARLISLE COMPANIES.
Executive leadership at CARLISLE COMPANIES.
DC
D. Christian Koch
Detailed
Chair, President and Chief Executive Officer
CEO
CB
Christopher B. Gaskill
Detailed
Vice President and General Counsel
FJ
Frank J. Ready
Detailed
President, Carlisle Weatherproofing Technologies
JT
Jason Taylor
Detailed
President, Carlisle Construction Materials
KP
Kevin P. Zdimal
Detailed
Vice President and Chief Financial Officer
SC
Scott C. Selbach
Detailed
Executive Vice President, Government Relations and Secretary
Board of directors at CARLISLE COMPANIES.
Research analysts who have asked questions during CARLISLE COMPANIES earnings calls.
Bryan Blair
Oppenheimer
6 questions for CSL
Also covers: AOS, DCI, ESAB +12 more
Garik Shmois
Loop Capital Markets
6 questions for CSL
Also covers: ACA, AMWD, AWI +13 more
SM
Susan Maklari
Goldman Sachs Group Inc.
6 questions for CSL
Also covers: ALH, AOS, AWI +24 more
KH
Keith Hughes
Truist Financial Corporation
4 questions for CSL
Also covers: AMRZ, AWI, BLD +21 more
TW
Timothy Wojs
Robert W. Baird & Co.
4 questions for CSL
Also covers: AAON, ALLE, AMWD +13 more
AB
Adam Baumgarten
Zelman & Associates
3 questions for CSL
Also covers: AMWD, AWI, AZEK +12 more
David Macgregor
Longbow Research
3 questions for CSL
Also covers: AOS, BECN, GRMN +14 more
JN
Joseph Nolan
Longbow Research
3 questions for CSL
Also covers: ALLE, BC, GRMN +3 more
TS
Tomohiko Sano
JPMorgan Chase & Co.
3 questions for CSL
Also covers: ALH, ALLE, AOS +4 more
SB
Saree Boroditsky
Jefferies
2 questions for CSL
Also covers: AOS, APH, EMR +15 more
TW
Tim Wojs
Robert W. Baird & Co. Incorporated
2 questions for CSL
Also covers: AAON, ALLE, AYI +5 more
Recent press releases and 8-K filings for CSL.
CSL announces five-year results for HEMGENIX gene therapy
CSL
- CSL announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study for HEMGENIX, confirming the long-term durability and safety of the one-time gene therapy for adults with hemophilia B.
- The study demonstrated that 94% of patients (51 of 54) remained free from continuous prophylaxis treatment through five years, with mean factor IX activity levels sustained at 36.1% at year five.
- HEMGENIX significantly reduced bleeding rates, with the mean adjusted annualized bleeding rate (ABR) for all bleeds decreasing by approximately 90% (from 4.16 to 0.40) from lead-in to year five.
- The therapy maintained a favorable safety profile, with no serious adverse events related to treatment, and is the only commercially available gene therapy for adults with hemophilia B.
Dec 7, 2025, 5:01 PM
Carlisle Reports Q3 2025 Results and Updates Full-Year Guidance
CSL
Earnings
Guidance Update
Share Buyback
- Carlisle (CSL) reported Q3 2025 revenue of $1.3 billion, an increase of 1% year-over-year, and adjusted EPS of $5.61.
- The company revised its full-year 2025 guidance to anticipate flat revenue year-over-year and an adjusted EBITDA margin decline of approximately 250 basis points.
- Performance was driven by the strength of the underlying CCM business, particularly strong reroofing demand, which was partially offset by ongoing challenges in residential and non-residential new construction markets.
- Carlisle maintained its commitment to capital deployment, repurchasing 800,000 shares for $300 million in Q3, raising its dividend by 10%, and increasing its full-year share buyback target to $1.3 billion.
- The company also issued $1 billion of debt in Q3, maintaining a net debt to EBITDA ratio of 1.4 times as of September 30, 2025.
Oct 29, 2025, 9:00 PM
Carlisle Companies Announces Q3 2025 Results and Revised Full-Year Outlook
CSL
Earnings
Guidance Update
Share Buyback
Demand Weakening
- CSL reported Q3 2025 revenue of $1,347 million, a 1% year-over-year increase, with Adjusted EPS of $5.61 and an Adjusted EBITDA Margin of 25.9%.
- The company returned $347 million to shareholders in Q3 2025 through dividends and share repurchases, and increased its share buyback target for the year to $1.3 billion.
- CSL revised its full-year 2025 outlook to project flat revenue year-over-year and an Adjusted EBITDA margin compression of 250 basis points from 2024.
- Performance was influenced by M&A contributions and strong commercial re-roofing, which helped to offset lower volumes from soft new construction and residential R&R markets.
Oct 29, 2025, 9:00 PM
Carlisle Companies Incorporated Announces Q3 2025 Results and Updates Full-Year Guidance
CSL
Earnings
Guidance Update
Share Buyback
- Carlisle Companies Incorporated reported Q3 2025 revenue of $1.3 billion, a 1% year-over-year increase, though organic revenue declined 2%.
- Adjusted EPS was $5.61, down 3% from the prior year, with an adjusted EBITDA margin of 25.9%, a 170 basis point decrease.
- The company revised its full-year 2025 guidance, now expecting consolidated revenue to be flat year-over-year and adjusted EBITDA margin to decline approximately 250 basis points.
- Carlisle increased its full-year 2025 share buyback target to $1.3 billion and announced a 10% dividend increase, its 49th consecutive annual increase.
Oct 29, 2025, 9:00 PM
Carlisle Companies Reports Q3 2025 Earnings
CSL
Earnings
Guidance Update
Share Buyback
- Carlisle Companies reported Q3 2025 revenue of $1.3 billion, a 1% year-over-year increase, and adjusted EPS of $5.61, a 3% decrease.
- The Carlisle Construction Materials (CCM) segment showed resilience with strong reroofing demand, maintaining an adjusted EBITDA margin of over 30%, while the Carlisle Weatherproofing Technologies (CWT) segment continued to be negatively impacted by soft new construction and residential markets.
- The company repurchased 800,000 shares for $300 million in Q3 2025, raised its dividend by 10%, and increased its full-year 2025 share buyback target to $1.3 billion.
- Carlisle updated its full-year 2025 outlook, expecting consolidated revenue to be flat year-over-year and adjusted EBITDA margins to decline approximately 250 basis points compared to 2024.
Oct 29, 2025, 9:00 PM
CSL Vifor and Travere Therapeutics Acknowledge Updated KDIGO Guidelines for IgA Nephropathy
CSL
- CSL Vifor and Travere Therapeutics support the recently published KDIGO 2025 clinical practice guidelines for IgA Nephropathy (IgAN), which define diagnostic criteria, treatment goals, and treatment approaches for the disease.
- The updated guidelines suggest treatment with FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), as a potential first-line approach for IgAN-induced nephron loss, noting its proven efficacy compared to optimized RASi in clinical trials.
- The PROTECT Study, a Phase 3 trial, showed that FILSPARI achieved a 49.8% mean reduction in proteinuria from baseline after 36 weeks, significantly outperforming the 15.1% reduction seen in irbesartan-treated patients.
- FILSPARI is a non-immunosuppressive therapy approved in the U.S. and Europe, and has been launched in Germany, Austria, Switzerland, Luxembourg, and the UK.
Sep 26, 2025, 6:30 AM
Carlisle Companies Reports Q1 2025 Results and Reaffirms Full-Year Outlook
CSL
Earnings
Guidance Update
Share Buyback
- Carlisle Companies reported Q1 2025 revenue of $1.1 billion, which was essentially flat year-over-year, and adjusted EPS of $3.61, despite facing challenges from continued weakness in residential construction markets and unfavorable winter weather.
- The company reaffirmed its 2025 outlook, anticipating mid-single-digit revenue growth for the full year, adjusted EBITDA margin expansion of approximately 50 basis points, and full-year adjusted EPS growth expected to exceed 10% year-over-year, with projected free cash flow of approximately $1 billion.
- Key drivers include strong reroofing activity, which represents 70% of CCM's commercial business, and the successful integration of the MTL acquisition, now expected to deliver over $20 million in synergies.
- Carlisle plans to deploy approximately $1 billion into share repurchases in 2025 and remains on track with its Vision 2030 target of $40+ adjusted EPS and cumulative free cash flow of more than $6 billion.
Apr 23, 2025, 9:00 PM
Quarterly earnings call transcripts for CARLISLE COMPANIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more